Real-world survival of Danish patients with HER2-positive metastatic breast cancer.

Daniel ArtziTobias BergAlan CelikIben KümlerJulia KenholmSami Al-RawiMaj-Britt JensenMichael AnderssonAnn Knoop

Published in: Acta oncologica (Stockholm, Sweden) (2023)

We found that only half of the patients with HER2-positive mBC, received first and second-line treatment according to national guidelines. Patients receiving treatment according to guidelines had a significantly higher median OS compared to patients who did not. We also found that patients with ER-negative disease or high tumor burden had a significantly higher risk of developing brain metastases.

Keyphrases

metastatic breast cancer
brain metastases
small cell lung cancer
combination therapy
clinical practice
risk factors
replacement therapy
endoplasmic reticulum